STOCK TITAN

Aurora Spine - ASAPF STOCK NEWS

Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.

Aurora Spine Corporation (ASAPF) delivers innovative spinal implant technologies focused on minimally invasive surgical solutions and regenerative approaches. This news hub provides investors and healthcare professionals with essential updates on the company’s financial developments, product milestones, and clinical advancements.

Access timely announcements including quarterly earnings reports, regulatory approvals for new devices, and strategic partnerships within the medical device sector. Our curated collection ensures transparent tracking of Aurora Spine’s progress in improving spinal care through screwless implant systems and biointegrated solutions.

Discover press releases covering FDA clearances, research collaborations, and executive leadership changes that shape the company’s trajectory. All content is verified for accuracy and relevance to support informed decision-making about ASAPF’s market position and technological contributions.

Bookmark this page for streamlined access to Aurora Spine’s latest developments in spinal healthcare innovation. Check regularly for updates on patent filings, clinical trial results, and industry recognition of their patient-focused medical devices.

Rhea-AI Summary

Aurora Spine Corporation (TSXV: ASG; OTCQB: ASAPF) has announced it will release its financial results for the second quarter ended June 30, 2022, on August 29, 2022. The management will host a conference call that same day at 11:00 a.m. Eastern Time to discuss the results. Interested parties can access the call via phone or a live webcast. Aurora Spine is dedicated to developing innovative medical devices aimed at improving spinal surgery outcomes. The company urges caution regarding forward-looking statements, as actual results may vary significantly due to various risks and uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.62%
Tags
-
Rhea-AI Summary

Aurora Spine Corporation (OTCQB: ASAPF) announced FDA clearance for its ZIP™ series of minimally invasive spinal implants to treat Lumbar Spinal Stenosis, expanding its indications beyond degenerative disc disease and spondylolisthesis. This new indication aims to address a growing patient population, estimated to increase by 18 million over the next decade. The ZIP device features a patented one-step locking mechanism, reducing surgery time and recovery. CEO Trent Northcutt highlighted this achievement as a key milestone for Aurora, enhancing patient care options while supporting the company's growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.87%
Tags
none
-
Rhea-AI Summary

Aurora Spine Corporation (ASAPF) recently announced the issuance of United States Patent No: 11,331,199 for its ZIPFlex™ Technology. This patent covers a minimally invasive interlaminar implant designed for motion preservation and fusion in spinal surgeries. The ZIPFlex device allows surgeons to perform motion preservation operations or convert to fusion procedures as necessary. This innovation could enhance treatment options for patients suffering from lumbar spinal degenerative diseases. The company emphasizes its focus on simplifying complex surgical solutions for improved patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.18%
Tags
none
Rhea-AI Summary

Aurora Spine Corporation (ASAPF) announced FDA 510(k) clearance for its innovative DEXA SOLO-L spinal fusion system, a first-of-its-kind 3D printed standalone ALIF device tailored to match patients' bone density. This development enhances Aurora's DEXA Technology Platform, marking a significant advancement in spinal surgery by personalizing implants. The CEO, Trent Northcutt, emphasized the potential for increased sales and surgeon adoption. This approval follows the company's commitment to innovation and expands their product range, previously including the DEXA-C cervical implant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
none
-
Rhea-AI Summary

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its financial results for Q1 2022 on May 23, 2022. This will be followed by a conference call scheduled for May 24, 2022, at 11:00 a.m. ET to discuss the results. The call can be accessed via phone at (844) 861-5497 or through a live webcast. A replay will be available until May 31, 2022. Aurora Spine specializes in designing innovative spinal implant technologies aimed at enhancing surgical outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
-
Rhea-AI Summary

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced it will release its financial results for Q4 2021 on April 29, 2022. A conference call is scheduled for May 2, 2022, at 11:00 a.m. ET to discuss these results. The call can be accessed by phone or via webcast. Aurora Spine specializes in innovative medical devices aimed at enhancing spinal surgery outcomes and is focused on minimally invasive technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.86%
Tags
Rhea-AI Summary

Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will participate in the Lytham Partners Spring 2022 Investor Conference from April 4-7, 2022. The Company will host a panel discussion titled Simplifying the Complex – A Panel Discussion with Doctors that use Aurora Products on April 4 at 11:00 am ET, available on its website. Additionally, management will engage in virtual one-on-one meetings throughout the event. The webcast will be archived for later viewing. Aurora Spine specializes in innovative, minimally invasive spinal implant technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
conferences
-
Rhea-AI Summary

Aurora Spine Corporation has achieved a significant milestone with the world's first surgical implantation of the DEXA-C patient matched implant at Cypress Pointe Surgical Hospital in Louisiana. This innovative device customizes spinal implants based on a patient's bone density, enhancing surgical outcomes and expanding access for older patients. Supported by peer-reviewed research, DEXA-C aims to reduce implant subsidence and improve fusion success rates. With the integration of Echolight technology, surgeons can now ensure the right implant density is selected for each patient, marking a transformative step in personalized spine surgery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
none
-
Rhea-AI Summary

Aurora Spine Corporation (TSXV: ASG | OTCQB: ASAPF) announced a joint co-marketing agreement with Echolight Medical on February 24, 2022. This partnership focuses on integrating Aurora’s DEXA Technology-based spinal implants with Echolight’s radiation-free EchoS densitometer for assessing bone health. The collaboration aims to enhance patient care by providing quick and accurate bone quality analysis, which will aid in selecting appropriate spinal implants. Both companies anticipate improved healthcare access and increased support for orthopedic and spinal treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none
Rhea-AI Summary

Aurora Spine Corporation reports strong preliminary results for Q4 and FY2021, with a projected revenue increase of approximately 23% to about $3.0 million and over $10.5 million, respectively. Sales of ZIP® products surged by 145%, while SiLO™ SI Joint fusion devices contributed 10% to Q4 sales, up 84%. The company has introduced innovative products including the APOLLO™ cervical plate and DEXA-C™ cervical interbody system, expected to enhance market share. The U.S. SI Joint market alone is valued at $2.6 billion, presenting significant opportunities for growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.32%
Tags
Aurora Spine

OTC:ASAPF

ASAPF Rankings

ASAPF Stock Data

17.86M
57.22M
26.02%
0%
Medical Devices
Healthcare
Link
Canada
Toronto